Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations

Journal of the American College of Cardiology

Volumn 34, Issue 1, 1999, Pages 106-112

  Flaker, Greg C ^a   Warnica, J Wayne ^b   Sacks, Frank M ^c   Moyé, Lemuel A ^d   Davis, Barry R ^d   Rouleau, Jean L ^e   Webel, Richard R ^a   Pfeffer, Marc A ^c  

^a UNIVERSITY OF MISSOURI   (United States)

^b FOOTHILLS HOSPITAL   (Canada)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PRAVASTATIN; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033165564     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00145-X     Document Type: Article

References (23)

1. American Heart Association; Heart and Stroke Statistical Update, 1998.
2. MARS Research Group , Blankenhorn D.H., Azen S.P., Kramsch D.M., et al. Coronary angiographic changes with lovastatin therapy. Ann Intern Med. 119:1993;969-976.
3. MAAS Investigators . Effect of simvastatin on coronary atheroma the multicentre antiatheroma study (MAAS) . Lancet. 334:1994;633-638.
4. CCAIT study group , Waters D., Higginson L., Gladstone P., et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation. 89:1994;959-968.
5. REGRESS Study Group , Jukema J.W., Bruschke A.V.G., vanBoven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation. 91:1995;2528-2540.
6. Cholesterol and Recurrent Events Trial Investigators , Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
7. West of Scotland Coronary Prevention Study Group , Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
8. AFCAPS/TexCAPS Research Group , Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
9. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The Cholesterol and Recurrent Events Trial Rationale, design and baseline characteristics of secondary prevention trial of lowering serum cholesterol and myocardial infarction . Am J Cardiol. 68:1991;1436-1446.
10. Cholesterol and Recurrent Events Clinical Trial Investigators , Pfeffer M.A., Sacks F.M., Moye L.A., et al. Cholesterol and Recurrent Events trial a secondary prevention trial for normolipidemic patients . Am J Cardiol. 76:1995;98C-106C.
11. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAMA. 53:1958;457-481.
12. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-89.
13. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators , Boden W.E., O'Rourke R.A., Crawford M.H., et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 338:1998;1785-1792.
14. PREDICT Trial investigators , Bertrand M.E., McFadden E.P., Fruchart J., et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol. 30:1997;863-869.
15. Lovastatin Restenosis Trial Study Group , Weintraub W.S., Boccuzzi S.J., Klein L., et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 331:1994;1331-1337.
16. Steele P.M., Chesebro J.H., Stanson A.W., et al. Balloon angioplasty natural history of the pathophysiologic response to injury in a pig model . Circ Res. 57:1985;105-112.
17. Ip J.H., Fuster V., Badimon L., Badimon J., Taubman M.B., Chesebro J.H. Syndromes of accelerated atherosclerosis role of vascular injury and smooth muscle cell proliferation . J Am Coll Cardiol. 1:1990;1667-1687.
18. Austin G.E., Ratliff N.B., Hollman J., Tabeil S., Phillips D. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after coronary angioplasty. J Am Coll Cardiol. 6:1985;369-375.
19. Holmes DR, Vlietstra R, Smith H, et al. Restenosis after coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77-81C.
20. Serruys P.W., Luijten H.E., Beatt K.J., et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, and 3 months. Circulation. 77:1988;361-372.
21. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L. Beneficial effects of combined co-niacin therapy on coronary atherosclerosis and coronary artery bypass grafts. JAMA. 257:1987;3233-3240.
22. Post Coronary Artery Bypass Graft Trial Investigators . The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-162.
23. Sacks F.M., Moye L.A., Davis B.R., et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation. 97:1998;1446-1452.